Donald Delwood, MD
Internal Medicine · Columbia, MONPI 1720036981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,500 of the $83,934 with a category attached, or 63.7%. Amgen accounts for 85.4% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2023 at $41,785 and has fallen 60.3% since, to $16,596 in 2025. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 840 payments — averaging $99.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$72K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Abbott$784
- AbbVie$709
- plus $7K from 42 others
What the payments were for
- Speaking & faculty fees$53,50064%
- Travel & lodging$13,86917%
- Food & beverage$16,42120%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$68,276
- AREXVY$230
- Kerendia$226
- FARXIGA$219
- NURTEC ODT$201
- Vascepa$125
- EVENITY$125
- BREZTRI AEROSPHERE$123
- FreeStyle Libre$122
- VRAYLAR$119
- FREESTYLE LIBRE 3$112
- REXULTI$111
- Omnia$107
- Otezla$103
- MOUNJARO$102
How this compares
$83,934 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 206 | $200,367 |
| OzempicSemaglutide | 55 | $101,091 |
| EliquisApixaban | 98 | $95,160 |
| JardianceEmpagliflozin | 53 | $78,604 |
| Praluent PenAlirocumab | 52 | $37,688 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $36,935 |
| TrulicityDulaglutide | 21 | $35,216 |
| Repatha SyringeEvolocumab | 27 | $33,071 |
| KerendiaFinerenone | 21 | $21,756 |
| ProliaDenosumab | 11 | $19,423 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,243 |
| MyrbetriqMirabegron | 16 | $16,204 |
| VascepaIcosapent Ethyl | 25 | $11,550 |
| PremarinEstrogens, Conjugated | 17 | $9,181 |
| Risedronate Sodium | 76 | $8,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin, Abrysvo | $395 | $111,889141 claims |
| Novo NordiskOzempic | $1,014 | $101,09155 claims |
| Boehringer IngelheimJardiance | $305 | $78,60453 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $652 | $53,17970 claims |
| Lilly USA, LLCTrulicity | $1,387 | $35,21621 claims |
| BayerKerendia | $686 | $21,75621 claims |
| AmgenProlia | $71,701 | $19,42311 claims |
| Astellas Pharma US IncMyrbetriq | $240 | $16,20416 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $1,442 | $10,05124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Columbia
- Dima DandachiColumbia$157K
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.